Related Experiment Video
Updated: Jun 15, 2026
10:17
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
[Hepatitis C and metabolic syndrome].
Reyes Aparcero López1, José Antonio Del Campo, Manuel Romero-Gómez
1Unidad de Gestión Clínica de Enfermedades Digestivas, Hospital Universitario de Valme, Sevilla, España.
Gastroenterologia Y Hepatologia
|March 9, 2010
Summary
Insulin resistance negatively impacts hepatitis C treatment outcomes. Adding metformin to standard therapy improved cure rates in women and patients with normalized insulin sensitivity, suggesting a therapeutic benefit.
Area of Science:
- Hepatology
- Endocrinology
- Pharmacology
Background:
- Insulin resistance is a key factor influencing treatment response in hepatitis C patients.
- It diminishes interferon sensitivity, disrupts intracellular signaling, and exacerbates liver damage through steatosis and fibrosis.
- Specific molecular pathways involving SOCS3 and PTPs are implicated in blocking interferon and insulin signaling.
Purpose of the Study:
- To investigate the impact of insulin resistance on hepatitis C treatment.
- To evaluate the efficacy of insulin-sensitizing agents in improving treatment outcomes.
- To assess the role of metformin in combination therapy for hepatitis C.
Main Methods:
- Analysis of treatment response in hepatitis C patients with varying degrees of insulin resistance.
- Evaluation of intracellular signaling pathways affected by insulin resistance.
- Clinical trial (TRIC-1 study) assessing the addition of metformin to peginterferon and ribavirin therapy.
Main Results:
- Insulin resistance was identified as a predictive factor for treatment response.
- Metformin addition to standard treatment improved cure rates in women and patients with improved insulin sensitivity.
- Normalization of insulin sensitivity during treatment correlated with better outcomes.
Conclusions:
- Addressing insulin resistance is crucial for optimizing hepatitis C treatment.
- Metformin, an insulin-sensitizing agent, shows promise as an adjunct therapy.
- Targeting insulin resistance pathways may enhance interferon-based therapies for hepatitis C.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:19Overview of Carbohydrate Metabolism
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...